ATE399020T1 - Erythropoietin reduziert die chemotherapiebedingte in-vivo-toxizität - Google Patents

Erythropoietin reduziert die chemotherapiebedingte in-vivo-toxizität

Info

Publication number
ATE399020T1
ATE399020T1 AT02725577T AT02725577T ATE399020T1 AT E399020 T1 ATE399020 T1 AT E399020T1 AT 02725577 T AT02725577 T AT 02725577T AT 02725577 T AT02725577 T AT 02725577T AT E399020 T1 ATE399020 T1 AT E399020T1
Authority
AT
Austria
Prior art keywords
vivo toxicity
erythropoietin
cytotoxic agent
reduces chemotherapy
erythropoietin reduces
Prior art date
Application number
AT02725577T
Other languages
English (en)
Inventor
George Sigounas
Paul Mehlhop
Original Assignee
Univ East Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23082337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE399020(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ East Carolina filed Critical Univ East Carolina
Application granted granted Critical
Publication of ATE399020T1 publication Critical patent/ATE399020T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AT02725577T 2001-04-09 2002-04-08 Erythropoietin reduziert die chemotherapiebedingte in-vivo-toxizität ATE399020T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28262101P 2001-04-09 2001-04-09

Publications (1)

Publication Number Publication Date
ATE399020T1 true ATE399020T1 (de) 2008-07-15

Family

ID=23082337

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02725577T ATE399020T1 (de) 2001-04-09 2002-04-08 Erythropoietin reduziert die chemotherapiebedingte in-vivo-toxizität

Country Status (22)

Country Link
US (2) US20020169128A1 (de)
EP (1) EP1377164B1 (de)
JP (1) JP4428924B2 (de)
KR (1) KR100885525B1 (de)
CN (2) CN101152565A (de)
AT (1) ATE399020T1 (de)
AU (1) AU2002256133B2 (de)
BR (1) BR0208727A (de)
CA (1) CA2443025A1 (de)
DE (1) DE60227244D1 (de)
DK (1) DK1377164T3 (de)
ES (1) ES2309166T3 (de)
HU (1) HUP0303838A3 (de)
IL (3) IL158155A0 (de)
MX (1) MXPA03009182A (de)
NO (1) NO20034504L (de)
NZ (1) NZ528675A (de)
PL (1) PL373361A1 (de)
PT (1) PT1377164E (de)
RU (1) RU2296563C2 (de)
WO (1) WO2002080676A1 (de)
ZA (1) ZA200307803B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
CA2471363C (en) 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
DK1629007T3 (da) * 2003-05-12 2009-06-29 Affymax Inc Hidtil ukendte peptider som binder til erythropoietin-receptoren
ES2395413T3 (es) * 2003-05-12 2013-02-12 Affymax, Inc. Péptidos que se unen al receptor de eritropoyetina
EA010015B1 (ru) * 2003-05-12 2008-06-30 Афимакс, Инк. Новый разделительный фрагмент (спейсер) для модифицированных полиэтиленгликолем соединений на основе пептидов
NZ544024A (en) * 2003-05-12 2009-06-26 Affymax Inc Novel poly(ethylene glycol) modified compounds and uses thereof
US20080312201A1 (en) * 2004-09-10 2008-12-18 Patrick Fogarty Reduced Toxicity Methotrexate Formulations and Methods for Using the Same
CN101142234A (zh) * 2004-11-11 2008-03-12 阿费麦克斯公司 结合红细胞生成素受体的新肽
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
CA2661054A1 (en) * 2006-08-22 2008-02-28 Chugai Seiyaku Kabushiki Kaisha Prophylactic and/or therapeutic agents for peripheral neuropathy
US20080249001A1 (en) * 2006-10-25 2008-10-09 Ajinomoto Co. Inc. Agents that alleviate side-effects caused by chemotherapy agents
EP1992355A1 (de) * 2007-05-16 2008-11-19 Eberhardt Spanuth Pharmazeutische Kombinationsmedikation mit NSAIDs oder zytoxischen Wirkstoffen
US10695402B2 (en) 2017-03-16 2020-06-30 University Of Rochester Erythropoietin for gastrointestinal dysfunction
WO2022159414A1 (en) 2021-01-22 2022-07-28 University Of Rochester Erythropoietin for gastroinfestinal dysfunction

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859765A (en) * 1983-10-17 1989-08-22 Syntex (U.S.A.) Inc. Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture
US4863857A (en) * 1985-03-01 1989-09-05 Board Of Regents, The University Of Texas System Polypeptide complementary to peptides or proteins having an amino acid sequence or nucleotide coding sequence at least partially known
NZ215865A (en) * 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
IT210425Z2 (it) * 1987-01-22 1988-12-30 Erga Srl Portachiavi con mezzo di scrittura telescopico incorporato
US4853871A (en) * 1987-04-06 1989-08-01 Genex Corporation Computer-based method for designing stablized proteins
US4856871A (en) * 1987-08-31 1989-08-15 General Electric Company Replaceable laser and lens assembly
JP2632014B2 (ja) * 1988-03-03 1997-07-16 中外製薬株式会社 骨髄機能障害性貧血治療剤
US20020052309A1 (en) * 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury
US6719977B1 (en) * 1998-02-12 2004-04-13 The General Hospital Corporation Methods to potentiate cancer therapies
CN1367701A (zh) * 1999-05-11 2002-09-04 奥索－麦克尼尔药物公司 红细胞生成素给药的药代动力学和药效模型
US6531121B2 (en) * 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs

Also Published As

Publication number Publication date
JP4428924B2 (ja) 2010-03-10
PL373361A1 (en) 2005-08-22
RU2003132584A (ru) 2005-04-10
CA2443025A1 (en) 2002-10-17
CN1499927A (zh) 2004-05-26
HUP0303838A3 (en) 2010-03-29
KR20030087064A (ko) 2003-11-12
AU2002256133B2 (en) 2007-05-31
NZ528675A (en) 2006-10-27
CN100379446C (zh) 2008-04-09
US20020169128A1 (en) 2002-11-14
KR100885525B1 (ko) 2009-02-26
JP2004532840A (ja) 2004-10-28
ZA200307803B (en) 2005-02-09
IL158155A0 (en) 2004-03-28
US20110195046A1 (en) 2011-08-11
NO20034504L (no) 2003-12-09
EP1377164B1 (de) 2008-06-25
IL198783A0 (en) 2010-02-17
BR0208727A (pt) 2005-05-10
HUP0303838A2 (hu) 2004-03-01
IL158155A (en) 2009-12-24
MXPA03009182A (es) 2004-02-17
NO20034504D0 (no) 2003-10-08
DK1377164T3 (da) 2008-10-13
EP1377164A1 (de) 2004-01-07
DE60227244D1 (de) 2008-08-07
RU2296563C2 (ru) 2007-04-10
CN101152565A (zh) 2008-04-02
ES2309166T3 (es) 2008-12-16
WO2002080676A1 (en) 2002-10-17
PT1377164E (pt) 2008-09-30
EP1377164A4 (de) 2005-05-04

Similar Documents

Publication Publication Date Title
IL198783A0 (en) Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
TR200401029T4 (tr) Asilfenil-üre türevleri, imalat yöntemleri ve ilaç maddesi olarak kullanımları
AR026938A1 (es) Combinaciones de productos activos fungicidas.
MXPA04000877A (es) Derivados retinoides con actividades antiangiogenicas, antitumorales y proapoptoticas.
IL173203A0 (en) Novel cyano thiazolides, methods for the production thereof, and use thereof as a medicament
ECSP066493A (es) Combinaciones sinérgicas de productos activos, fungicidas
HUP0203652A2 (hu) GCSF-konjugátumok
MY147211A (en) Novel dihydropseudoerythromycin derivatives
BRPI0412851A (pt) benzamidazóis de n-metila-substituìdos
AU2002311886A1 (en) Process for preparing purified shilajit composition from native shilajit
WO2002100437A3 (en) Ophthalmic compositions comprising hyaluronic acid
DK1161228T3 (da) Præparat omfattende isoquercetin og ascorbinsyre i en sustained release-form
DE60125417D1 (de) Verminderung der nebenwirkungen der chemotherapie in krebspatienten
BR0012696A (pt) Composição oftálmica
DE69708340D1 (de) Arylsulfonylimidazolon-derivate als antitumormittel
BR0311642A (pt) Formulação de divalproex de sódio de liberação aumentada
EE05241B1 (et) Distamtsiini a-halogenoakrlolderivaadi kasutamine
MXPA01007210A (es) Agente para el tratamiento de enfermedad de parkinson que comprende un agente que mejora la funcion del astrocito como ingrediente activo.
DE602005023288D1 (de) Sulfopyranosylacylglycerol-Derivate zur Anwendung in Kombination mit Bestrahlung in einer Tumor-Radiotherapie
BR0010699A (pt) Benzimidazóis substituìdos, sua produção e utilização dos mesmos como agente contra protozoários parasitários
MXPA05008711A (es) Uso de r-10-hidroxi-10,11-dihidro-carbamazepina en dolor neuropatico.
EP1930023A3 (de) Erythropoietin reduziert die Chemotherapie-induzierte in vivo Toxizität
EP2266566A3 (de) Nicotinamid Derivate und ihrer Verwendung als Therapeutika
ATE241640T1 (de) Fusidinsäure-derivate
WO2004091508A3 (en) Fullerene compositions for ameliorating dermatological conditions

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1377164

Country of ref document: EP

REN Ceased due to non-payment of the annual fee